Hydroxyureamethyl Acylfulvene for Treating Brain Cancer or CNS Cancer
Summary
The European Patent Office published patent EP4132489A1 on April 1, 2026, granting Lantern Pharma Inc. exclusive rights to hydroxyureamethyl acylfulvene for treating brain cancer or CNS cancer. The patent names inventors Kulkarni and Bhatia and covers the compound, formulations, and methods of treatment using the drug. This provides Lantern Pharma with patent protection in 34 EPC contracting states for 20 years from the filing date.
What changed
EPO published patent EP4132489A1 granting Lantern Pharma Inc. exclusive intellectual property rights to hydroxyureamethyl acylfulvene for treating brain cancer and CNS cancer. The patent covers the chemical compound, pharmaceutical formulations, and methods of medical treatment. Inventors are listed as Kulkarni and Bhatia.
Competitors developing similar acylfulvene derivatives for brain or CNS cancer applications should conduct freedom-to-operate analyses to avoid potential infringement. Generic drug manufacturers and biotech companies working in this therapeutic area may need to consider licensing options or design-around strategies when this patent expires.
What to do next
- Monitor for updates
Archived snapshot
Apr 9, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
HYDROXYUREAMETHYL-ACYLFULVENE FOR TREATING BRAIN CANCER OR CNS CANCER
Publication EP4132489A1 Kind: A1 Apr 01, 2026
Applicants
Lantern Pharma Inc.
Inventors
KULKARNI, Aditya, BHATIA, Kishor
IPC Classifications
A61K 31/122 20060101AFI20240430BHEP C07C 35/37 20060101ALI20240430BHEP C07C 49/727 20060101ALI20240430BHEP C07C 49/755 20060101ALI20240430BHEP A61P 35/00 20060101ALI20240430BHEP A61K 31/17 20060101ALN20240430BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for ChangeBridge: EPO Bulletin - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ChangeBridge: EPO Bulletin - Therapeutics (A61P) publishes new changes.